Pharmacokinetics, brain delivery, and efficacy in brain tumor-bearing mice of glutathione pegylated liposomal doxorubicin (2B3-101)

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Gaillard, Pieter J ^a   Appeldoorn, Chantal C M ^a   Dorland, Rick ^a   Van Kregten, Joan ^a   Manca, Francesca ^a   Vugts, Danielle J ^b   Windhorst, Bert ^b   Van Dongen, Guus A M S ^b   De Vries, Helga E ^b   Maussang, David ^a   Van Tellingen, Olaf ^c  

^a To BBB Technologies BV   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON 14; DOXORUBICIN; GLUTATHIONE; GLUTATHIONE PEGYLATED LIPOSOMAL DOXORUBICIN; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOLUMINESCENCE; BLOOD BRAIN BARRIER; BRAIN CAPILLARY ENDOTHELIAL CELL; CANCER INHIBITION; CANCER REGRESSION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BINDING; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG EXPOSURE; DRUG RETENTION; DRUG TOLERANCE; DRUG UPTAKE; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; MOUSE; NONHUMAN; NUDE MOUSE; SURVIVAL TIME; TEMPERATURE DEPENDENCE; TUMOR MODEL; TUMOR XENOGRAFT;

ANIMALS; BODY WEIGHT; BRAIN; BRAIN NEOPLASMS; CAPILLARIES; CELL PROLIFERATION; DOXORUBICIN; DRUG DELIVERY SYSTEMS; ENDOTHELIAL CELLS; FEMALE; GLIOBLASTOMA; GLUTATHIONE; HUMANS; MICE; MICE, NUDE; POLYETHYLENE GLYCOLS; SURVIVAL ANALYSIS; TIME FACTORS; TISSUE DISTRIBUTION; TREATMENT OUTCOME;

EID: 84897408101     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0082331     Document Type: Article

References (48)

1. Laquintana V, Trapani A, Denora N, Wang F, Gallo JM, et al. (2009) New strategies to deliver anticancer drugs to brain tumors. Expert Opin Drug Deliv 6: 1017-1032.
2. Walbert T, Gilbert MR (2009) The role of chemotherapy in the treatment of patients with brain metastases from solid tumors. Int J Clin Oncol 14: 299-306.
3. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, et al. (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996. (Pubitemid 40349501)
4. Lu-Emerson C, Eichler AF (2012) Brain metastases. Continuum (Minneap Minn) 18: 295-311.
5. de Vries NA, Beijnen JH, Boogerd W, van Tellingen O (2006) Blood-brain barrier and chemotherapeutic treatment of brain tumors. Expert Rev Neurother 6: 1199-1209. (Pubitemid 44231977)
6. Palmieri D, Chambers AF, Felding-Habermann B, Huang S, Steeg PS (2007) The biology of metastasis to a sanctuary site. Clin Cancer Res 13: 1656-1662. (Pubitemid 46957363)
7. Fidler IJ (2011) The role of the organ microenvironment in brain metastasis. Semin Cancer Biol 21: 107-112.
8. Agarwal S, Manchanda P, Vogelbaum MA, Ohlfest JR, Elmquist WF (2013) Function of the blood-brain barrier and restriction of drug delivery to invasive glioma cells: findings in an orthotopic rat xenograft model of glioma. Drug Metab Dispos 41: 33-39.
9. Tosoni A, Franceschi E, Brandes AA (2008) Chemotherapy in breast cancer patients with brain metastases: have new chemotherapic agents changed the clinical outcome? Crit Rev Oncol Hematol 68: 212-221.
10. Perry J, Chambers A, Spithoff K, Laperriere N (2007) Gliadel wafers in the treatment of malignant glioma: a systematic review. Curr Oncol 14: 189-194.
11. La Rocca RV, Rezazadeh A (2011) Carmustine-impregnated wafers and their impact in the management of high-grade glioma. Expert Opin Pharmacother 12: 1325-1332.
12. de Boer AG, Gaillard PJ (2007) Drug targeting to the brain. Annu Rev Pharmacol Toxicol 47: 323-355.
13. Gaillard PJ, Visser CC, Appeldoorn CCM, Rip J (2012) Enhanced brain drug delivery: safely crossing the blood-brain barrier. Drug Discovery Today: Technologies 9: e155-e160.
14. Pardridge WM (2007) Brain drug development and brain drug targeting. Pharm Res 24: 1729-1732.
15. Kannan R, Chakrabarti R, Tang D, Kim KJ, Kaplowitz N (2000) GSH transport in human cerebrovascular endothelial cells and human astrocytes: evidence for luminal localization of Na+-dependent GSH transport in HCEC. Brain Res 852: 374-382. (Pubitemid 30035175)
16. Kannan R, Kuhlenkamp JF, Jeandidier E, Trinh H, Ookhtens M, et al. (1990) Evidence for carrier-mediated transport of glutathione across the blood-brain barrier in the rat. J Clin Invest 85: 2009-2013. (Pubitemid 20192980)
17. Zlokovic BV, Mackic JB, McComb JG, Weiss MH, Kaplowitz N, et al. (1994) Evidence for transcapillary transport of reduced glutathione in vascular perfused guinea-pig brain. Biochem Biophys Res Commun 201: 402-408. (Pubitemid 24213740)
18. Gaillard PJ, Appeldoorn CC, Rip J, Dorland R, van der Pol SM, et al. (2012) Enhanced brain delivery of liposomal methylprednisolone improved therapeutic efficacy in a model of neuroinflammation. J Control Release 164: 364-369.
19. Lindqvist A, Rip J, Gaillard PJ, Bjorkman S, Hammarlund-Udenaes M (2013) Enhanced Brain Delivery of the Opioid Peptide DAMGO in Glutathione PEGylated Liposomes: A Microdialysis Study. Mol Pharm. 10(5): 1553-1541.
20. Liedtke C, Wang J, Tordai A, Symmans WF, Hortobagyi GN, et al. (2009) Clinical evaluation of chemotherapy response predictors developed from breast cancer cell lines. Breast Cancer Res Treat 121(2): 301-309.
21. Wolff JE, Trilling T, Molenkamp G, Egeler RM, Jurgens H (1999) Chemosensitivity of glioma cells in vitro: a meta analysis. J Cancer Res Clin Oncol 125: 481-486. (Pubitemid 29410412)
22. Tardi PG, Boman NL, Cullis PR (1996) Liposomal doxorubicin. J Drug Target 4: 129-140. (Pubitemid 26390295)
23. Lesniak MS, Upadhyay U, Goodwin R, Tyler B, Brem H (2005) Local delivery of doxorubicin for the treatment of malignant brain tumors in rats. Anticancer Res 25: 3825-3831. (Pubitemid 41665151)
24. Voulgaris S, Partheni M, Karamouzis M, Dimopoulos P, Papadakis N, et al. (2002) Intratumoral doxorubicin in patients with malignant brain gliomas. Am J Clin Oncol 25: 60-64.
25. von Holst H, Knochenhauer E, Blomgren H, Collins VP, Ehn L, et al. (1990) Uptake of adriamycin in tumour and surrounding brain tissue in patients with malignant gliomas. Acta Neurochir (Wien) 104: 13-16.
26. Arnold RD, Mager DE, Slack JE, Straubinger RM (2005) Effect of repetitive administration of Doxorubicin-containing liposomes on plasma pharmacokinetics and drug biodistribution in a rat brain tumor model. Clin Cancer Res 11: 8856-8865. (Pubitemid 43005938)
27. Siegal T, Horowitz A, Gabizon A (1995) Doxorubicin encapsulated in sterically stabilized liposomes for the treatment of a brain tumor model: biodistribution and therapeutic efficacy. J Neurosurg 83: 1029-1037. (Pubitemid 26048143)
28. Fabel K, Dietrich J, Hau P, Wismeth C, Winner B, et al. (2001) Long-term stabilization in patients with malignant glioma after treatment with liposomal doxorubicin. Cancer 92: 1936-1942. (Pubitemid 32952514)
29. Glas M, Koch H, Hirschmann B, Jauch T, Steinbrecher A, et al. (2007) Pegylated liposomal doxorubicin in recurrent malignant glioma: analysis of a case series. Oncology 72: 302-307. (Pubitemid 351238141)
30. Hau P, Fabel K, Baumgart U, Rummele P, Grauer O, et al. (2004) Pegylated liposomal doxorubicin-efficacy in patients with recurrent high-grade glioma. Cancer 100: 1199-1207. (Pubitemid 38325948)
31. Kemper EM, Leenders W, Kusters B, Lyons S, Buckle T, et al. (2006) Development of luciferase tagged brain tumour models in mice for chemotherapy intervention studies. Eur J Cancer 42: 3294-3303. (Pubitemid 44854510)
32. Barenholz Y (2012) Doxil(R) - the first FDA-approved nano-drug: lessons learned. J Control Release 160: 117-134.
33. Weksler BB, Subileau EA, Perriere N, Charneau P, Holloway K, et al. (2005) Blood-brain barrier-specific properties of a human adult brain endothelial cell line. FASEB J 19: 1872-1874. (Pubitemid 41598779)
34. van Asperen J, van Tellingen O, Beijnen JH (1998) Determination of doxorubicin and metabolites in murine specimens by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 712: 129-143.
35. Klerk CP, Overmeer RM, Niers TM, Versteeg HH, Richel DJ, et al. (2007) Validity of bioluminescence measurements for noninvasive in vivo imaging of tumor load in small animals. Biotechniques 43: 7-13, 30.
36. Dai H, Marbach P, Lemaire M, Hayes M, Elmquist WF (2003) Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux. J Pharmacol Exp Ther 304: 1085-1092. (Pubitemid 36254421)
37. Gaillard PJ, Visser CC, de Boer M, Appeldoorn CCM, Rip J (2013, accepted for publication) Blood-to-brain drug delivery using nanocarriers. In: Hammarlund-Udenaes M, de Lange E, Thorne R, editors. Drug delivery to the brain - physiological concepts, methodologies and approaches: Springer.
38. Whitaker G, Lunte CE (2010) Investigation of microdialysis sampling calibration approaches for lipophilic analytes: doxorubicin. J Pharm Biomed Anal 53: 490-496.
39. Anders CK, Adamo B, Karginova O, Deal AM, Rawal S, et al. (2013) Pharmacokinetics and Efficacy of PEGylated Liposomal Doxorubicin in an Intracranial Model of Breast Cancer. PLoS One 8: e61359.
40. Aryal M, Vykhodtseva N, Zhang YZ, Park J, McDannold N (2013) Multiple treatments with liposomal doxorubicin and ultrasound-induced disruption of blood-tumor and blood-brain barriers improve outcomes in a rat glioma model. J Control Release 169: 103-111.
41. Rip J, Appeldoorn CCM, Manca FM, Dorland R, van Kregten JMR, et al. (2010) Receptor-mediated delivery of drugs across the blood-brain barrier. Presented at: Pharmacology and Toxicology of the Blood-Brain Barrier: State of the Art, Needs for Future Research and Expected Benefits for the EU. Brussels, Belgium.
42. Block KI, Koch AC, Mead MN, Tothy PK, Newman RA, et al. (2008) Impact of antioxidant supplementation on chemotherapeutic toxicity: a systematic review of the evidence from randomized controlled trials. Int J Cancer 123: 1227-1239.
43. Joshi G, Aluise CD, Cole MP, Sultana R, Pierce WM, et al. (2010) Alterations in brain antioxidant enzymes and redox proteomic identification of oxidized brain proteins induced by the anti-cancer drug adriamycin: implications for oxidative stress-mediated chemobrain. Neuroscience 166: 796-807.
44. O'Brien ME, Wigler N, Inbar M, Rosso R, Grischke E, et al. (2004) Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 15: 440-449. (Pubitemid 38444547)
45. Regina A, Demeule M, Che C, Lavallee I, Poirier J, et al. (2008) Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep-2. Br J Pharmacol 155: 185-197.
46. Che C, Yang G, Thiot C, Lacoste MC, Currie JC, et al. (2010) New Angiopep-modified doxorubicin (ANG1007) and etoposide (ANG1009) chemotherapeutics with increased brain penetration. J Med Chem 53: 2814-2824.
47. Kurzrock R, Gabrail N, Moulder S, Noles C, Smith C, et al. (2009) ANG1005: Results of a phase I study in patients with advanced solid tumors and metastatic brain cancer. Mol Cancer Ther 8: B168.
48. Kurzrock R, Gabrail N, Chandhasin C, Moulder S, Smith C, et al. (2012) Safety, pharmacokinetics, and activity of GRN1005, a novel conjugate of angiopep-2, a peptide facilitating brain penetration, and paclitaxel, in patients with advanced solid tumors. Mol Cancer Ther 11: 308-316.